V

Vimian Group AB
STO:VIMIAN

Watchlist Manager
Vimian Group AB
STO:VIMIAN
Watchlist
Price: 37.45 SEK -2.09%
Market Cap: 19.4B SEK
Have any thoughts about
Vimian Group AB?
Write Note

Vimian Group AB
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vimian Group AB
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
V
Vimian Group AB
STO:VIMIAN
Other Long-Term Assets
€1.9m
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
OssDsign AB
STO:OSSD
Other Long-Term Assets
kr1k
CAGR 3-Years
0%
CAGR 5-Years
-85%
CAGR 10-Years
N/A
Xvivo Perfusion AB
STO:XVIVO
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
D
Doxa AB
STO:DOXA
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bactiguard Holding AB
STO:BACTI B
Other Long-Term Assets
kr10.8m
CAGR 3-Years
2 108%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
S2Medical AB (publ)
STO:S2M
Other Long-Term Assets
kr1k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Vimian Group AB
Glance View

Market Cap
19.6B SEK
Industry
Health Care

Vimian Group AB is a relatively new player making waves in the veterinary and animal health industries. Founded in Sweden, Vimian is structured as a conglomerate composed of specialized subsidiaries focused on different niche markets within veterinary services, diagnostics, and technology. This strategic structure enables the company to operate across various segments such as Veterinary Services, Specialty Pharma, MedTech, and Diagnostics, achieving a holistic approach to animal healthcare. By acquiring and partnering with innovative companies globally, Vimian capitalizes on synergies and cross-market opportunities, ensuring a competitive edge in each of its operational fields. The company’s diverse portfolio allows it to cater not only to pet owners and veterinary professionals but also to livestock industries, ensuring comprehensive coverage in the growing market of animal welfare and health. Vimian’s revenue streams are multi-faceted, generated from a blend of product sales, subscriptions, and service fees. For instance, within its Specialty Pharma segment, the company develops and sells pharmaceutical products designed to treat common and specialty conditions in animals, thus generating continuous revenue from veterinary practices worldwide. In the MedTech segment, Vimian offers cutting-edge medical devices and equipment, enhancing veterinary surgical and diagnostic capabilities, which drives sales. Meanwhile, their Diagnostics division provides innovative testing solutions that help veterinarians identify and treat animal diseases accurately, offering another lucrative revenue stream. This multi-pronged business model not only mitigates risk through diversification but also positions Vimian as a key player in meeting the rapidly evolving demands of animal health and care.

VIMIAN Intrinsic Value
45.26 SEK
Undervaluation 17%
Intrinsic Value
Price
V

See Also

What is Vimian Group AB's Other Long-Term Assets?
Other Long-Term Assets
1.9m EUR

Based on the financial report for Sep 30, 2024, Vimian Group AB's Other Long-Term Assets amounts to 1.9m EUR.

What is Vimian Group AB's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 3Y
11%

Over the last year, the Other Long-Term Assets growth was -29%. The average annual Other Long-Term Assets growth rates for Vimian Group AB have been 11% over the past three years .

Back to Top